Renal effects of human urotensin-II in rats with experimental congestive heart failure.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Nephrology, Dialysis and Transplantation

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/NDT/GFK049PMID 16396970
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response

  2004cited by this paper
• Pharmacology of the Urotensin-II Receptor Antagonist ACT-058362: First Demonstration of a Pathophysiological Role of the Urotensin System

  2004cited by this paper
• Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

  2004cited by this paper
• Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

  2003cited by this paper
• Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney.

  2003influential reference
• Congestive heart failure and expression of myocardial urotensin II.

  2002cited by this paper
• Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma

  2002cited by this paper
• Plasma Urotensin in Human Systolic Heart Failure

  2002influential reference
• Depressor and regionally‐selective vasodilator effects of human and rat urotensin II in conscious rats

  2001cited by this paper
• Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues

  2001cited by this paper
• Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure.

  2001cited by this paper
• Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

  2000cited by this paper
• Mechanisms of big endothelin-1-induced diuresis and natriuresis : role of ET(B) receptors.

  2000cited by this paper
• Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries.

  2000cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999influential reference
• Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction

  1999influential reference
• Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide.

  1998cited by this paper
• Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.

  1998cited by this paper
• Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide.

  1998cited by this paper
• Hormonal determinants of sodium excretion in rats with experimental high-output heart failure.

  1988cited by this paper
• Renal and circulatory mechanisms in congestive heart failure.

  1987cited by this paper
• Complex effects of Gillichthys urotensin II on rat aortic strips

  1987cited by this paper
• Stimulation of sodium transport across the teleost urinary bladder by urotensin II.

  1981cited by this paper

• Urotensin II system in chronic kidney disease

  2024cites this paper
• Urotensin receptor antagonist palosuran attenuates cyclosporine-a-induced nephrotoxicity in rats.

  2019cites this paper
• 14.11 – Vasoactive Substances as Mediators of Renal Injury

  2018cites this paper
• Use of Diverse Chemometric and Validation Methods to Accurately Predict Human Urotensin-II Receptor Antagonist Activity.

  2015cites this paper
• Decrease of Urotensin II activity can impact on the volume status in predialysis chronic kidney disease

  2015cites this paper
• Pressor and renal regional hemodynamic effects of urotensin II in neonatal pigs

  2013cites this paper
• Urotensin-II: More Than a Mediator for Kidney

  2012cites this paper
• Vasoactive Molecules and the Kidney

  2012cites this paper
• Disorders of Sodium Balance

  2012cites this paper
• Potential Clinical Implications of the Urotensin II Receptor Antagonists

  2011cites this paper
• Role of Novel Biomarkers in Chronic Kidney Disease: Urotensin II

  2010cites this paper
• Vasoactive Substances As Mediators of Renal Injury

  2010cites this paper
• Urotensin II alters vascular reactivity in animals subjected to volume overload.

  2010cites this paper
• Urotensin-II receptor modulators as potential drugs.

  2010cites this paper
• Clinical significance of endogenous vasoactive neurohormones in chronic systolic heart failure.

  2010cites this paper
• Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure.

  2009cites this paper
• Human urotensin-II receptor desensitisation

  2009cites this paper
• Urotensin II: lessons from comparative studies for general endocrinology.

  2008cites this paper
• Urotensin II and Cardiomyopathy in End-Stage Renal Disease

  2008cites this paper
• Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II.

  2008cites this paper
• Renal haemodynamic and tubular actions of urotensin II in the rat.

  2008influential citation
• Urotensin II: a cardiovascular and renal update

  2008cites this paper
• Urotensin II: A New Pharmacologic Target in the Treatment of Cardiovascular Disease

  2008influential citation
• Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension

  2007cites this paper
• Renal and vascular actions of urotensin II.

  2006influential citation
• The role of urotensin II in cardiovascular and renal physiology and diseases

  2006cites this paper